CD19

CD19 is a surface glycoprotein of the immunoglobulin gene superfamily. It is expressed during all stages of B cell development until terminal plasma cell differentiation and is considered the earliest and broadest B-cell marker. CD19 forms a signal transduction complex on the surface of B cells with CD21, CD81, and CD225, which reduce the threshold for antigen-initiated B cell activation. CD19 is also involved in B cell development and immunoglobulin-mediate B cell activation.

Most B cell cancers express normal or high levels of CD19, making it a useful biomarker for B-cell malignancies, including B cell lymphomas, acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Additionally, because CD19 expression is restricted to B cells and follicular dendritic cells, CD19 is a primary target for B cell lymphoma and leukemia therapies, such as bispecific antibodies and CAR-T cell therapies.

Imanis offers tumor cell line models for studies of CD19-positive cancers and CD19-targeted therapies (alone or in combination with CD20). These models have characterized CD19 expression combined with stable reporter expression for cell tracking in vivo. Additionally, CD19 cell panels include CD19 positive and CD19 negative cell lines on the same cell background for controlled experiments in vitro or in vivo.

Cell lines can be purchased individually or at a discounted rate for pairs/panels.